Novavax, Inc. ( $NVAX ) http://novavax.com/asse

Novavax, Inc. ( $NVAX )



Shares of this vaccine developer could give your portfolio a shot in the arm this year. Novavax develops vaccines for administration across life stages – from infants to older adults – focusing on the prevention of diseases ranging from the seasonal flu to the Ebola and Zika viruses. This company also brings some longevity to the table, having been founded in 1987.

Novavax stock plunged in December 2017 when the markets reacted poorly to an update on one of the company's influenza vaccines. However, there are other promising products in the pipeline, including a vaccine for respiratory syncytial virus, which causes significant hospitalizations and deaths among children around the world. The hurdles that remain for the clinical approval of its products make Novavax a risky stock, but a bringing a successful vaccine to market could imply significant profits. (See also: How to Pick Winning Penny Stocks.)

Average Volume: 11,838,093
Market Cap: $665.852 million
P/E Ratio (TTM): N/A
EPS (TTM): -$0.63


Read more: Top 3 Healthcare Penny Stocks for 2018 | Investopedia https://www.investopedia.com/investing/health...z5Bt7jhcFB
Follow us: Investopedia on Facebook